世界の神経変性疾患治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Neurodegenerative Disease Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4565 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、神経変性疾患治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（神経伝達物質、神経保護剤、生物製剤、その他）、用途別市場規模（多発性硬化症[MS]、アルツハイマー病、パーキンソン病、急性片頭痛、自閉症、麻薬性麻痺、筋萎縮性側索硬化症[ALS]、注意欠陥活動亢進障害[ADHD]、脊髄性筋萎縮症、ハンチントン病）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・神経変性疾患治療の市場動向 ・企業の競争状況、市場シェア ・神経変性疾患治療の種類別市場規模と予測2016-2027（神経伝達物質、神経保護剤、生物製剤、その他） ・神経変性疾患治療の用途別市場規模と予測2016-2027（多発性硬化症[MS]、アルツハイマー病、パーキンソン病、急性片頭痛、自閉症、麻薬性麻痺、筋萎縮性側索硬化症[ALS]、注意欠陥活動亢進障害[ADHD]、脊髄性筋萎縮症、ハンチントン病） ・神経変性疾患治療の北米市場規模2016-2027（アメリカ、カナダ） ・神経変性疾患治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・神経変性疾患治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・神経変性疾患治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・神経変性疾患治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Allergan plc、Bayer AG、F. Hoffmann La-Roche Ltd.、GlaxoSmithKline plc、Johnson & Johnson、Merck KGaA、Novartis AG、Pfizer, Inc.、Sanofi、Teva Pharmaceutical Industries Ltd.） ・結論

Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.

Market Analysis and Insights: Global Neurodegenerative Disease Treatment Market
The global Neurodegenerative Disease Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neurodegenerative Disease Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neurodegenerative Disease Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neurodegenerative Disease Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neurodegenerative Disease Treatment market.

Global Neurodegenerative Disease Treatment Scope and Market Size
Neurodegenerative Disease Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Disease Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Neurotransmitter Agents
Neuroprotective Agents
Biologics
Others

Segment by Application
Multiple Sclerosis [MS]
Alzheimer’s Disease
Parkinson’s Disease
Acute Migraine
Autism
Narcolepsy
Amyotrophic Lateral Sclerosis [ALS]
Attention Deficit Hyperactivity Disorder [ADHD]
Spinal Muscular Atrophy

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Allergan plc
Bayer AG
F. Hoffmann La-Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson
Merck KGaA
Novartis AG
Pfizer, Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disease Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Neurotransmitter Agents
1.2.3 Neuroprotective Agents
1.2.4 Biologics
1.2.5 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Disease Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Multiple Sclerosis [MS]
1.3.3 Alzheimer’s Disease
1.3.4 Parkinson’s Disease
1.3.5 Acute Migraine
1.3.6 Autism
1.3.7 Narcolepsy
1.3.8 Amyotrophic Lateral Sclerosis [ALS]
1.3.9 Attention Deficit Hyperactivity Disorder [ADHD]
1.3.10 Spinal Muscular Atrophy
1.3.11 Huntington’s Disease
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Neurodegenerative Disease Treatment Market Perspective (2016-2027)
2.2 Neurodegenerative Disease Treatment Growth Trends by Regions
2.2.1 Neurodegenerative Disease Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neurodegenerative Disease Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Neurodegenerative Disease Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Neurodegenerative Disease Treatment Industry Dynamic
2.3.1 Neurodegenerative Disease Treatment Market Trends
2.3.2 Neurodegenerative Disease Treatment Market Drivers
2.3.3 Neurodegenerative Disease Treatment Market Challenges
2.3.4 Neurodegenerative Disease Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Disease Treatment Players by Revenue
3.1.1 Global Top Neurodegenerative Disease Treatment Players by Revenue (2016-2021)
3.1.2 Global Neurodegenerative Disease Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Neurodegenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Disease Treatment Revenue
3.4 Global Neurodegenerative Disease Treatment Market Concentration Ratio
3.4.1 Global Neurodegenerative Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease Treatment Revenue in 2020
3.5 Neurodegenerative Disease Treatment Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Disease Treatment Product Solution and Service
3.7 Date of Enter into Neurodegenerative Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Neurodegenerative Disease Treatment Breakdown Data by Type
4.1 Global Neurodegenerative Disease Treatment Historic Market Size by Type (2016-2021)
4.2 Global Neurodegenerative Disease Treatment Forecasted Market Size by Type (2022-2027)

5 Neurodegenerative Disease Treatment Breakdown Data by Application
5.1 Global Neurodegenerative Disease Treatment Historic Market Size by Application (2016-2021)
5.2 Global Neurodegenerative Disease Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Neurodegenerative Disease Treatment Market Size (2016-2027)
6.2 North America Neurodegenerative Disease Treatment Market Size by Type
6.2.1 North America Neurodegenerative Disease Treatment Market Size by Type (2016-2021)
6.2.2 North America Neurodegenerative Disease Treatment Market Size by Type (2022-2027)
6.2.3 North America Neurodegenerative Disease Treatment Market Size by Type (2016-2027)
6.3 North America Neurodegenerative Disease Treatment Market Size by Application
6.3.1 North America Neurodegenerative Disease Treatment Market Size by Application (2016-2021)
6.3.2 North America Neurodegenerative Disease Treatment Market Size by Application (2022-2027)
6.3.3 North America Neurodegenerative Disease Treatment Market Size by Application (2016-2027)
6.4 North America Neurodegenerative Disease Treatment Market Size by Country
6.4.1 North America Neurodegenerative Disease Treatment Market Size by Country (2016-2021)
6.4.2 North America Neurodegenerative Disease Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Neurodegenerative Disease Treatment Market Size (2016-2027)
7.2 Europe Neurodegenerative Disease Treatment Market Size by Type
7.2.1 Europe Neurodegenerative Disease Treatment Market Size by Type (2016-2021)
7.2.2 Europe Neurodegenerative Disease Treatment Market Size by Type (2022-2027)
7.2.3 Europe Neurodegenerative Disease Treatment Market Size by Type (2016-2027)
7.3 Europe Neurodegenerative Disease Treatment Market Size by Application
7.3.1 Europe Neurodegenerative Disease Treatment Market Size by Application (2016-2021)
7.3.2 Europe Neurodegenerative Disease Treatment Market Size by Application (2022-2027)
7.3.3 Europe Neurodegenerative Disease Treatment Market Size by Application (2016-2027)
7.4 Europe Neurodegenerative Disease Treatment Market Size by Country
7.4.1 Europe Neurodegenerative Disease Treatment Market Size by Country (2016-2021)
7.4.2 Europe Neurodegenerative Disease Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disease Treatment Market Size (2016-2027)
8.2 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Type
8.2.1 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Application
8.3.1 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region
8.4.1 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Neurodegenerative Disease Treatment Market Size (2016-2027)
9.2 Latin America Neurodegenerative Disease Treatment Market Size by Type
9.2.1 Latin America Neurodegenerative Disease Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Neurodegenerative Disease Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Neurodegenerative Disease Treatment Market Size by Type (2016-2027)
9.3 Latin America Neurodegenerative Disease Treatment Market Size by Application
9.3.1 Latin America Neurodegenerative Disease Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Neurodegenerative Disease Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Neurodegenerative Disease Treatment Market Size by Application (2016-2027)
9.4 Latin America Neurodegenerative Disease Treatment Market Size by Country
9.4.1 Latin America Neurodegenerative Disease Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Neurodegenerative Disease Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disease Treatment Market Size (2016-2027)
10.2 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Type
10.2.1 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Application
10.3.1 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country
10.4.1 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Allergan plc
11.1.1 Allergan plc Company Details
11.1.2 Allergan plc Business Overview
11.1.3 Allergan plc Neurodegenerative Disease Treatment Introduction
11.1.4 Allergan plc Revenue in Neurodegenerative Disease Treatment Business (2016-2021)
11.1.5 Allergan plc Recent Development
11.2 Bayer AG
11.2.1 Bayer AG Company Details
11.2.2 Bayer AG Business Overview
11.2.3 Bayer AG Neurodegenerative Disease Treatment Introduction
11.2.4 Bayer AG Revenue in Neurodegenerative Disease Treatment Business (2016-2021)
11.2.5 Bayer AG Recent Development
11.3 F. Hoffmann La-Roche Ltd.
11.3.1 F. Hoffmann La-Roche Ltd. Company Details
11.3.2 F. Hoffmann La-Roche Ltd. Business Overview
11.3.3 F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Introduction
11.3.4 F. Hoffmann La-Roche Ltd. Revenue in Neurodegenerative Disease Treatment Business (2016-2021)
11.3.5 F. Hoffmann La-Roche Ltd. Recent Development
11.4 GlaxoSmithKline plc
11.4.1 GlaxoSmithKline plc Company Details
11.4.2 GlaxoSmithKline plc Business Overview
11.4.3 GlaxoSmithKline plc Neurodegenerative Disease Treatment Introduction
11.4.4 GlaxoSmithKline plc Revenue in Neurodegenerative Disease Treatment Business (2016-2021)
11.4.5 GlaxoSmithKline plc Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Neurodegenerative Disease Treatment Introduction
11.5.4 Johnson & Johnson Revenue in Neurodegenerative Disease Treatment Business (2016-2021)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck KGaA
11.6.1 Merck KGaA Company Details
11.6.2 Merck KGaA Business Overview
11.6.3 Merck KGaA Neurodegenerative Disease Treatment Introduction
11.6.4 Merck KGaA Revenue in Neurodegenerative Disease Treatment Business (2016-2021)
11.6.5 Merck KGaA Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Details
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Neurodegenerative Disease Treatment Introduction
11.7.4 Novartis AG Revenue in Neurodegenerative Disease Treatment Business (2016-2021)
11.7.5 Novartis AG Recent Development
11.8 Pfizer, Inc.
11.8.1 Pfizer, Inc. Company Details
11.8.2 Pfizer, Inc. Business Overview
11.8.3 Pfizer, Inc. Neurodegenerative Disease Treatment Introduction
11.8.4 Pfizer, Inc. Revenue in Neurodegenerative Disease Treatment Business (2016-2021)
11.8.5 Pfizer, Inc. Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Neurodegenerative Disease Treatment Introduction
11.9.4 Sanofi Revenue in Neurodegenerative Disease Treatment Business (2016-2021)
11.9.5 Sanofi Recent Development
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Details
11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Introduction
11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disease Treatment Business (2016-2021)
11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Neurodegenerative Disease Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Neurotransmitter Agents
Table 3. Key Players of Neuroprotective Agents
Table 4. Key Players of Biologics
Table 5. Key Players of Others
Table 6. Global Neurodegenerative Disease Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Neurodegenerative Disease Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Neurodegenerative Disease Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Neurodegenerative Disease Treatment Market Share by Regions (2016-2021)
Table 10. Global Neurodegenerative Disease Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Neurodegenerative Disease Treatment Market Share by Regions (2022-2027)
Table 12. Neurodegenerative Disease Treatment Market Trends
Table 13. Neurodegenerative Disease Treatment Market Drivers
Table 14. Neurodegenerative Disease Treatment Market Challenges
Table 15. Neurodegenerative Disease Treatment Market Restraints
Table 16. Global Neurodegenerative Disease Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Neurodegenerative Disease Treatment Market Share by Players (2016-2021)
Table 18. Global Top Neurodegenerative Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Disease Treatment as of 2020)
Table 19. Ranking of Global Top Neurodegenerative Disease Treatment Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Neurodegenerative Disease Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Neurodegenerative Disease Treatment Product Solution and Service
Table 23. Date of Enter into Neurodegenerative Disease Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Neurodegenerative Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Neurodegenerative Disease Treatment Revenue Market Share by Type (2016-2021)
Table 27. Global Neurodegenerative Disease Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Neurodegenerative Disease Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Neurodegenerative Disease Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Neurodegenerative Disease Treatment Revenue Market Share by Application (2016-2021)
Table 31. Global Neurodegenerative Disease Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Neurodegenerative Disease Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Neurodegenerative Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Neurodegenerative Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Neurodegenerative Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Neurodegenerative Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Neurodegenerative Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Neurodegenerative Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Neurodegenerative Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Neurodegenerative Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Neurodegenerative Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Neurodegenerative Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Neurodegenerative Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Neurodegenerative Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Neurodegenerative Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Neurodegenerative Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Neurodegenerative Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Neurodegenerative Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Neurodegenerative Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Neurodegenerative Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Neurodegenerative Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Neurodegenerative Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Neurodegenerative Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Neurodegenerative Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Neurodegenerative Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Neurodegenerative Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Neurodegenerative Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Neurodegenerative Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 63. Allergan plc Company Details
Table 64. Allergan plc Business Overview
Table 65. Allergan plc Neurodegenerative Disease Treatment Product
Table 66. Allergan plc Revenue in Neurodegenerative Disease Treatment Business (2016-2021) & (US$ Million)
Table 67. Allergan plc Recent Development
Table 68. Bayer AG Company Details
Table 69. Bayer AG Business Overview
Table 70. Bayer AG Neurodegenerative Disease Treatment Product
Table 71. Bayer AG Revenue in Neurodegenerative Disease Treatment Business (2016-2021) & (US$ Million)
Table 72. Bayer AG Recent Development
Table 73. F. Hoffmann La-Roche Ltd. Company Details
Table 74. F. Hoffmann La-Roche Ltd. Business Overview
Table 75. F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Product
Table 76. F. Hoffmann La-Roche Ltd. Revenue in Neurodegenerative Disease Treatment Business (2016-2021) & (US$ Million)
Table 77. F. Hoffmann La-Roche Ltd. Recent Development
Table 78. GlaxoSmithKline plc Company Details
Table 79. GlaxoSmithKline plc Business Overview
Table 80. GlaxoSmithKline plc Neurodegenerative Disease Treatment Product
Table 81. GlaxoSmithKline plc Revenue in Neurodegenerative Disease Treatment Business (2016-2021) & (US$ Million)
Table 82. GlaxoSmithKline plc Recent Development
Table 83. Johnson & Johnson Company Details
Table 84. Johnson & Johnson Business Overview
Table 85. Johnson & Johnson Neurodegenerative Disease Treatment Product
Table 86. Johnson & Johnson Revenue in Neurodegenerative Disease Treatment Business (2016-2021) & (US$ Million)
Table 87. Johnson & Johnson Recent Development
Table 88. Merck KGaA Company Details
Table 89. Merck KGaA Business Overview
Table 90. Merck KGaA Neurodegenerative Disease Treatment Product
Table 91. Merck KGaA Revenue in Neurodegenerative Disease Treatment Business (2016-2021) & (US$ Million)
Table 92. Merck KGaA Recent Development
Table 93. Novartis AG Company Details
Table 94. Novartis AG Business Overview
Table 95. Novartis AG Neurodegenerative Disease Treatment Product
Table 96. Novartis AG Revenue in Neurodegenerative Disease Treatment Business (2016-2021) & (US$ Million)
Table 97. Novartis AG Recent Development
Table 98. Pfizer, Inc. Company Details
Table 99. Pfizer, Inc. Business Overview
Table 100. Pfizer, Inc. Revenue in Neurodegenerative Disease Treatment Business (2016-2021) & (US$ Million)
Table 101. Pfizer, Inc. Recent Development
Table 102. Sanofi Company Details
Table 103. Sanofi Business Overview
Table 104. Sanofi Neurodegenerative Disease Treatment Product
Table 105. Sanofi Revenue in Neurodegenerative Disease Treatment Business (2016-2021) & (US$ Million)
Table 106. Sanofi Recent Development
Table 107. Teva Pharmaceutical Industries Ltd. Company Details
Table 108. Teva Pharmaceutical Industries Ltd. Business Overview
Table 109. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Product
Table 110. Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disease Treatment Business (2016-2021) & (US$ Million)
Table 111. Teva Pharmaceutical Industries Ltd. Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Disease Treatment Market Share by Type: 2020 VS 2027
Figure 2. Neurotransmitter Agents Features
Figure 3. Neuroprotective Agents Features
Figure 4. Biologics Features
Figure 5. Others Features
Figure 6. Global Neurodegenerative Disease Treatment Market Share by Application: 2020 VS 2027
Figure 7. Multiple Sclerosis [MS] Case Studies
Figure 8. Alzheimer’s Disease Case Studies
Figure 9. Parkinson's Disease Case Studies
Figure 10. Acute Migraine Case Studies
Figure 11. Autism Case Studies
Figure 12. Narcolepsy Case Studies
Figure 13. Amyotrophic Lateral Sclerosis [ALS] Case Studies
Figure 14. Attention Deficit Hyperactivity Disorder [ADHD] Case Studies
Figure 15. Spinal Muscular Atrophy Case Studies
Figure 16. Huntington's Disease Case Studies
Figure 17. Neurodegenerative Disease Treatment Report Years Considered
Figure 18. Global Neurodegenerative Disease Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 19. Global Neurodegenerative Disease Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 20. Global Neurodegenerative Disease Treatment Market Share by Regions: 2020 VS 2027
Figure 21. Global Neurodegenerative Disease Treatment Market Share by Regions (2022-2027)
Figure 22. Global Neurodegenerative Disease Treatment Market Share by Players in 2020
Figure 23. Global Top Neurodegenerative Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Disease Treatment as of 2020
Figure 24. The Top 10 and 5 Players Market Share by Neurodegenerative Disease Treatment Revenue in 2020
Figure 25. Global Neurodegenerative Disease Treatment Revenue Market Share by Type (2016-2021)
Figure 26. Global Neurodegenerative Disease Treatment Revenue Market Share by Type (2022-2027)
Figure 27. North America Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. North America Neurodegenerative Disease Treatment Market Share by Type (2016-2027)
Figure 29. North America Neurodegenerative Disease Treatment Market Share by Application (2016-2027)
Figure 30. North America Neurodegenerative Disease Treatment Market Share by Country (2016-2027)
Figure 31. United States Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Canada Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Europe Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Europe Neurodegenerative Disease Treatment Market Share by Type (2016-2027)
Figure 35. Europe Neurodegenerative Disease Treatment Market Share by Application (2016-2027)
Figure 36. Europe Neurodegenerative Disease Treatment Market Share by Country (2016-2027)
Figure 37. Germany Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. France Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. U.K. Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Italy Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Russia Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Nordic Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Asia-Pacific Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Asia-Pacific Neurodegenerative Disease Treatment Market Share by Type (2016-2027)
Figure 45. Asia-Pacific Neurodegenerative Disease Treatment Market Share by Application (2016-2027)
Figure 46. Asia-Pacific Neurodegenerative Disease Treatment Market Share by Region (2016-2027)
Figure 47. China Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Japan Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. South Korea Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Southeast Asia Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. India Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Australia Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Latin America Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Latin America Neurodegenerative Disease Treatment Market Share by Type (2016-2027)
Figure 55. Latin America Neurodegenerative Disease Treatment Market Share by Application (2016-2027)
Figure 56. Latin America Neurodegenerative Disease Treatment Market Share by Country (2016-2027)
Figure 57. Mexico Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Brazil Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Middle East & Africa Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Middle East & Africa Neurodegenerative Disease Treatment Market Share by Type (2016-2027)
Figure 61. Middle East & Africa Neurodegenerative Disease Treatment Market Share by Application (2016-2027)
Figure 62. Middle East & Africa Neurodegenerative Disease Treatment Market Share by Country (2016-2027)
Figure 63. Turkey Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 64. Saudi Arabia Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 65. UAE Neurodegenerative Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 66. Allergan plc Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2016-2021)
Figure 67. Bayer AG Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2016-2021)
Figure 68. F. Hoffmann La-Roche Ltd. Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2016-2021)
Figure 69. GlaxoSmithKline plc Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2016-2021)
Figure 70. Johnson & Johnson Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2016-2021)
Figure 71. Merck KGaA Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2016-2021)
Figure 72. Novartis AG Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2016-2021)
Figure 73. Pfizer, Inc. Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2016-2021)
Figure 74. Sanofi Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2016-2021)
Figure 75. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2016-2021)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed

---